Worldwide Clinical Trials, Inc. expanded its early phase clinical trial capabilities by opening its Bioanalytical Center of Excellence – a larger state-of-the-art lab in Austin, Texas. This investment builds on Worldwide’s recent addition of three key leadership roles and enables the company to optimally support preclinical and early phase development.
Aligned with Worldwide’s scientific heritage and 36-year history of operating top-ranking facilities, the bioanalytical lab is about 42,000 square feet with about 20 percent more usable space than the previous lab. It is outfitted with modern infrastructure, improved air control, and more efficient, fit-for-purpose lab space to flexibly support both current and future early phase research demands while enabling optimized workflows to ensure critical sponsor timelines are met.
The new bioanalytical lab is vital to Worldwide’s strategic approach to early phase study research in normal volunteers and specialized patient populations. During early phase clinical research, sponsors are focused on proving the viability of novel drug and scientific concepts, particularly regarding measures of exposure and selected pharmacodynamic endpoints, while ensuring subject safety. Speed of signal detection via bioanalytical testing is critical to accelerate sponsor decision-making during this period, determining if assets should be progressed to the next phase of research. The new lab’s proximity to Worldwide’s Clinical Pharmacology Unit allows for seamless sample transfer and rapid processing – a valuable benefit for our sponsors.
“Early phase clinical research is the foundational platform upon which innovative medical breakthroughs are built,” said Mike Mencer, Executive Vice President and General Manager, Early Phase, Worldwide. “It demands an unparalleled amount of forward-thinking and strategic rigor. Our Bioanalytical Center of Excellence builds on our investment in a growing team of experts to offer innovators the top-quality data collection and analysis they need for swift proof-of-concept validation and meaningful exit decision-making.”
“Bioanalytics is the heart and soul of early phase research,” added Peter Benton, President and Co-CEO, Worldwide. “That’s why it’s so gratifying to expand Worldwide’s ability to present sponsors with scientific knowledge and leading-edge technical capabilities that deliver high-quality data to inform critical decisions – with the ultimate goal of developing important new medications for patients."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!